Literature DB >> 15681506

Correlation of forced oscillation technique in preschool children with cystic fibrosis with pulmonary inflammation.

S Brennan1, G L Hall, F Horak, A Moeller, P M C Pitrez, A Franzmann, S Turner, N de Klerk, P Franklin, K R Winfield, E Balding, S M Stick, P D Sly.   

Abstract

BACKGROUND: Lung disease in cystic fibrosis (CF) is established in early childhood with recurrent bacterial infections and inflammation. Using spirometry, the effect of this early lung damage cannot be measured until a child is 6 years of age when some irreversible lung damage may already have occurred. Techniques for measurement of lung function in infants and young children include raised volume rapid thoracic compression (RVRTC) and low frequency forced oscillation (LFFOT). The aim of this study was to investigate the role of inflammation and infection on a population of infants and young children with CF and to determine whether lung function in this population (measured by LFFOT) is affected by early lung disease.
METHODS: Lung function was measured by LFFOT in 24 children undergoing bronchoalveolar lavage (BAL) on 27 occasions as part of an annual programme while still under general anaesthesia. Following lung function testing, three aliquots of saline were instilled into the right middle or lower lobe. The first aliquot retrieved was processed for the detection of microbes, and the remaining aliquots were pooled to assess inflammatory markers (cytology, IL-8, NE, LTB(4)).
RESULTS: Inflammation (percentage and number of neutrophils) was significantly higher in children with infections (p<0.001, p = 0.04, respectively), but not in those with symptoms. Several markers of inflammation significantly correlated with LFFOT parameters (R, G, and eta).
CONCLUSION: Infections and inflammation are established before symptoms are apparent. Inflammation is correlated with measures of parenchymal changes in lung function measured by LFFOT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681506      PMCID: PMC1747296          DOI: 10.1136/thx.2004.026419

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  23 in total

1.  Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis.

Authors:  Giovanna E Carpagnano; Peter J Barnes; Duncan M Geddes; Margaret E Hodson; Sergei A Kharitonov
Journal:  Am J Respir Crit Care Med       Date:  2003-04-15       Impact factor: 21.405

2.  Production of the potent neutrophil chemokine, growth-related protein alpha (GROalpha), is not elevated in cystic fibrosis children.

Authors:  H A Wyatt; A P Sampson; I M Balfour-Lynn; J F Price
Journal:  Respir Med       Date:  2000-02       Impact factor: 3.415

3.  Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis.

Authors:  Sarath C Ranganathan; Andrew Bush; Carol Dezateux; Siobhan B Carr; Ah-Fong Hoo; Sooky Lum; Su Madge; John Price; John Stroobant; Angie Wade; Colin Wallis; Hilary Wyatt; Janet Stocks
Journal:  Am J Respir Crit Care Med       Date:  2002-11-15       Impact factor: 21.405

Review 4.  Lung function testing in infants with cystic fibrosis: lessons from the past and future directions.

Authors:  M Gappa; S C Ranganathan; J Stocks
Journal:  Pediatr Pulmonol       Date:  2001-09

5.  Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.

Authors:  Carolyn J Dakin; Andrew H Numa; He Wang; John R Morton; Calypso C Vertzyas; Richard L Henry
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

6.  Altered respiratory tissue mechanics in asymptomatic wheezy infants.

Authors:  G L Hall; Z Hantos; P D Sly
Journal:  Am J Respir Crit Care Med       Date:  2001-10-15       Impact factor: 21.405

7.  Early airway infection, inflammation, and lung function in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood; Claire Wainwright
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

8.  Detecting early structural lung damage in cystic fibrosis.

Authors:  Harm A W M Tiddens
Journal:  Pediatr Pulmonol       Date:  2002-09

9.  Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis.

Authors:  M W Konstan; R W Walenga; K A Hilliard; J B Hilliard
Journal:  Am Rev Respir Dis       Date:  1993-10

10.  Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis.

Authors:  T P Dean; Y Dai; J K Shute; M K Church; J O Warner
Journal:  Pediatr Res       Date:  1993-08       Impact factor: 3.756

View more
  20 in total

Review 1.  New insights into pulmonary inflammation in cystic fibrosis.

Authors:  S Rao; J Grigg
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

2.  Early pulmonary disease manifestations in cystic fibrosis mice.

Authors:  Rebecca J Darrah; Anna L Mitchell; Cara K Campanaro; Eric S Barbato; Paul Litman; Abdus Sattar; Craig A Hodges; Mitchell L Drumm; Frank J Jacono
Journal:  J Cyst Fibros       Date:  2016-05-24       Impact factor: 5.482

3.  Risk stratification model to detect early pulmonary disease in infants with cystic fibrosis diagnosed by newborn screening.

Authors:  Lacrecia J Britton; Gabriela R Oates; Robert A Oster; Staci T Self; Robert B Troxler; Wynton C Hoover; Hector H Gutierrez; William T Harris
Journal:  Pediatr Pulmonol       Date:  2016-08-24

4.  Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis.

Authors:  Emanuela M Bruscia; Ping-Xia Zhang; Ayano Satoh; Christina Caputo; Ruslan Medzhitov; Ambika Shenoy; Marie E Egan; Diane S Krause
Journal:  J Immunol       Date:  2011-05-18       Impact factor: 5.422

5.  Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests.

Authors:  Sooky Lum; Per Gustafsson; Henrik Ljungberg; Georg Hülskamp; Andrew Bush; Siobhán B Carr; Rosemary Castle; Ah-Fong Hoo; John Price; Sarath Ranganathan; John Stroobant; Angie Wade; Colin Wallis; Hilary Wyatt; Janet Stocks
Journal:  Thorax       Date:  2006-11-22       Impact factor: 9.139

Review 6.  Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?

Authors:  Sarath C Ranganathan; Graham L Hall; Peter D Sly; Stephen M Stick; Tonia A Douglas
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

7.  Circadian disruption alters mouse lung clock gene expression and lung mechanics.

Authors:  Hélène Hadden; Steven J Soldin; Donald Massaro
Journal:  J Appl Physiol (1985)       Date:  2012-06-07

Review 8.  Endpoints for clinical trials in young children with cystic fibrosis.

Authors:  Stephanie D Davis; Alan S Brody; Mary J Emond; Lyndia C Brumback; Margaret Rosenfeld
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 9.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

10.  AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations.

Authors:  Rebecca J Darrah; Frank J Jacono; Neha Joshi; Anna L Mitchell; Abdus Sattar; Cara K Campanaro; Paul Litman; Jennifer Frey; David E Nethery; Eric S Barbato; Craig A Hodges; Harriet Corvol; Garry R Cutting; Michael R Knowles; Lisa J Strug; Mitchell L Drumm
Journal:  J Cyst Fibros       Date:  2018-06-22       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.